Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer

American Journal of Pathology

Volumn 182, Issue 2, 2013, Pages 339-349

  Fristrup, Niels ^a   Birkenkamp Demtröder, Karin ^a   Reinert, Thomas ^a   Sanchez Carbayo, Marta ^b   Segersten, Ulrika ^c   Malmström, Per Uno ^c   Palou, Joan ^d   Alvarez Múgica, Miguel ^e   Pan, Chin Chen ^f   Ulhøi, Benedicte P ^a   Borre, Michael ^a   Ørntoft, Torben F ^a   Dyrskjøt, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Structural Biology and Biocomputing Programme   (Spain)

^c UPPSALA UNIVERSITY   (Sweden)

^d FUNDACIÓ PUIGVERT   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; MINICHROMOSOME MAINTENANCE PROTEIN 7; PROTEIN; TRIM29 PROTEIN; UBE2C PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SPAIN; SWEDEN; TAIWAN; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; VALIDATION PROCESS; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; COHORT STUDIES; CYCLIN D1; DENMARK; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLES; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SPAIN; SWEDEN; TAIWAN; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-CONJUGATING ENZYMES; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84872724548     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.10.017     Document Type: Article

References (38)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. L.A. Kiemeney, J.A. Witjes, A.L. Verbeek, R.P. Heijbroek, and F.M. Debruyne The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group Br J Cancer 67 1993 806 812
3. M.S. Cookson, H.W. Herr, Z.F. Zhang, S. Soloway, P.C. Sogani, and W.R. Fair The treated natural history of high risk superficial bladder cancer: 15-year outcome J Urol 158 1997 62 67
4. L. Cheng, J.C. Cheville, R.M. Neumann, B.C. Leibovich, K.S. Egan, B.E. Spotts, and D.G. Bostwick Survival of patients with carcinoma in situ of the urinary bladder Cancer 85 1999 2469 2474
5. B. Ehdaie, and D. Theodorescu Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis Expert Rev Anticancer Ther 8 2008 1103 1110
6. Y.M. Hong, and K.R. Loughlin Economic impact of tumor markers in bladder cancer surveillance Urology 71 2008 131 135
7. R.J. Sylvester, A.P. van der Meijden, W. Oosterlinck, J.A. Witjes, C. Bouffioux, L. Denis, D.W. Newling, and K. Kurth Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 475
8. L. Dyrskjot Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics Expert Rev Mol Diagn 3 2003 635 647
9. L. Dyrskjot, K. Zieger, M. Kruhoffer, T. Thykjaer, J.L. Jensen, H. Primdahl, N. Aziz, N. Marcussen, K. Moller, and T.F. Orntoft A molecular signature in superficial bladder carcinoma predicts clinical outcome Clin Cancer Res 11 2005 4029 4036
10. L. Dyrskjot, K. Zieger, F.X. Real, N. Malats, A. Carrato, C. Hurst, S. Kotwal, M. Knowles, P.U. Malmstrom, M. de la Torre, K. Wester, Y. Allory, D. Vordos, A. Caillault, F. Radvanyi, A.M. Hein, J.L. Jensen, K.M. Jensen, N. Marcussen, and T.F. Orntoft Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study Clin Cancer Res 13 2007 3545 3551
11. N. Fristrup, B.P. Ulhoi, K. Birkenkamp-Demtroder, F. Mansilla, M. Sanchez-Carbayo, U. Segersten, P.U. Malmstrom, A. Hartmann, J. Palou, M. Alvarez-Mugica, K. Zieger, M. Borre, T.F. Orntoft, and L. Dyrskjot Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer Am J Pathol 180 2012 1824 1834
12. S. Heeboll, M. Borre, P.D. Ottosen, C.L. Andersen, F. Mansilla, L. Dyrskjot, T.F. Orntoft, and N. Torring SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation Histol Histopathol 23 2008 1069 1076
13. K. Soreide Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research J Clin Pathol 62 2009 1 5
14. F. Mansilla, K. Birkenkamp-Demtroder, M. Kruhoffer, F.B. Sorensen, C.L. Andersen, P. Laiho, L.A. Aaltonen, H.W. Verspaget, and T.F. Orntoft Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups Br J Cancer 96 2007 1896 1903
15. L. Dyrskjot, T. Thykjaer, M. Kruhoffer, J.L. Jensen, N. Marcussen, S. Hamilton-Dutoit, H. Wolf, and T.F. Orntoft Identifying distinct classes of bladder carcinoma using microarrays Nat Genet 33 2003 90 96
16. M.B. Eisen, P.T. Spellman, P.O. Brown, and D. Botstein Cluster analysis and display of genome-wide expression patterns Proc Natl Acad Sci U S A 95 1998 14863 14868
17. M. Grunkin, J. Raundahl, and N.T. Foged Practical considerations of image analysis and quantification of signal transduction IHC staining Methods Mol Biol 717 2011 143 154
18. J. Fernandez-Gomez, R. Madero, E. Solsona, M. Unda, L. Martinez-Pineiro, A. Ojea, J. Portillo, M. Montesinos, M. Gonzalez, C. Pertusa, J. Rodriguez-Molina, J.E. Camacho, M. Rabadan, A. Astobieta, S. Isorna, P. Muntanola, A. Gimeno, M. Blas, and J.A. Martinez-Pineiro The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables Eur Urol 60 2011 423 430
19. M.S. Pepe, Z. Feng, H. Janes, P.M. Bossuyt, and J.D. Potter Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design J Natl Cancer Inst 100 2008 1432 1438
20. J.P. Alao The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention Mol Cancer 6 2007 24
21. S. Jirawatnotai, Y. Hu, W. Michowski, J.E. Elias, L. Becks, F. Bienvenu, A. Zagozdzon, T. Goswami, Y.E. Wang, A.B. Clark, T.A. Kunkel, H.T. van, B. Xia, M. Correll, J. Quackenbush, D.M. Livingston, S.P. Gygi, and P. Sicinski A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers Nature 474 2011 230 234
22. A. Lopez-Beltran, R.J. Luque, J. Alvarez-Kindelan, A. Quintero, F. Merlo, J.C. Carrasco, M.J. Requena, and R. Montironi Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1) Eur Urol 45 2004 606 612
23. A. Lopez-Beltran, R.J. Luque, J. Alvarez-Kindelan, A. Quintero, F. Merlo, M.J. Requena, and R. Montironi Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters Am J Clin Pathol 122 2004 444 452
24. A. Sgambato, M. Migaldi, B. Faraglia, A.G. De, P. Ferrari, R. Ardito, G.C. De, G. Capelli, A. Cittadini, and G.P. Trentini Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome Int J Cancer 97 2002 671 678
25. J.P. Chong, H.M. Mahbubani, C.Y. Khoo, and J.J. Blow Purification of an MCM-containing complex as a component of the DNA replication licensing system Nature 375 1995 418 421
26. Y. Ishimi A DNA helicase activity is associated with an MCM4, -6, and -7 protein complex J Biol Chem 272 1997 24508 24513
27. B. Ren, G. Yu, G.C. Tseng, K. Cieply, T. Gavel, J. Nelson, G. Michalopoulos, Y.P. Yu, and J.H. Luo MCM7 amplification and overexpression are associated with prostate cancer progression Oncogene 25 2006 1090 1098
28. G. Toyokawa, K. Masuda, Y. Daigo, H.S. Cho, M. Yoshimatsu, M. Takawa, S. Hayami, K. Maejima, M. Chino, H.I. Field, D.E. Neal, E. Tsuchiya, B.A. Ponder, Y. Maehara, Y. Nakamura, and R. Hamamoto Minichromosome maintenance protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer Mol Cancer 10 2011 65
29. A. Reymond, G. Meroni, A. Fantozzi, G. Merla, S. Cairo, L. Luzi, D. Riganelli, E. Zanaria, S. Messali, S. Cainarca, A. Guffanti, S. Minucci, P.G. Pelicci, and A. Ballabio The tripartite motif family identifies cell compartments EMBO J 20 2001 2140 2151
30. Z. Yuan, A. Villagra, L. Peng, D. Coppola, M. Glozak, E.M. Sotomayor, J. Chen, W.S. Lane, and E. Seto The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions Mol Cell Biol 30 2010 3004 3015
31. T. Sho, T. Tsukiyama, T. Sato, T. Kondo, J. Cheng, T. Saku, M. Asaka, and S. Hatakeyama TRIM29 negatively regulates p53 via inhibition of Tip60 Biochim Biophys Acta 1813 2011 1245 1253
32. S. Hatakeyama TRIM proteins and cancer Nat Rev Cancer 11 2011 792 804
33. L. Dyrskjot, M. Kruhoffer, T. Thykjaer, N. Marcussen, J.L. Jensen, K. Moller, and T.F. Orntoft Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification Cancer Res 64 2004 4040 4048
34. F. Stegmeier, M. Rape, V.M. Draviam, G. Nalepa, M.E. Sowa, X.L. Ang, E.R. McDonald III, M.Z. Li, G.J. Hannon, P.K. Sorger, M.W. Kirschner, J.W. Harper, and S.J. Elledge Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities Nature 446 2007 876 881
35. J.H. van Ree, K.B. Jeganathan, L. Malureanu, and J.M. van Deursen Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation J Cell Biol 188 2010 83 100
36. Z. Hao, H. Zhang, and J. Cowell Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker Tumour Biol 33 2011 723 730
37. Y. Okamoto, T. Ozaki, K. Miyazaki, M. Aoyama, M. Miyazaki, and A. Nakagawara UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme Cancer Res 63 2003 4167 4173
38. K.W. Wagner, L.M. Sapinoso, W. El-Rifai, H.F. Frierson, N. Butz, J. Mestan, F. Hofmann, Q.L. Deveraux, and G.M. Hampton Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin Oncogene 23 2004 6621 6629